Schizophrenia: Treatment targets beyond monoamine systems

Research output: Contribution to journalArticlepeer-review

54 Scopus citations


We develop the proposal in this review that schizophrenia is a syndrome made up of component symptom complexes, each with distinctive clinical correlates, pathophysiology, and selective treatments. Psychosis is the necessary component of the syndrome; it has a young-adult onset and is sensitive to current antipsychotic drugs. Cognitive dysfunction often precedes psychosis onset, does not present an episodic course, and is poorly responsive to antipsychotic drugs. Treatments for cognition are being developed largely on the basis of animal pharmacology. Drugs for component symptom complexes will theoretically be coadministered to independent symptomatic end points. Animal models, some with genetic characteristics, can be more easily and directly developed to match an individual component than to match an illness definition as broad as schizophrenia.

Original languageEnglish (US)
Pages (from-to)189-209
Number of pages21
JournalAnnual Review of Pharmacology and Toxicology
StatePublished - Feb 10 2011


  • acetylcholine
  • cognition
  • component symptom complexes
  • glutamate
  • psychosis

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology


Dive into the research topics of 'Schizophrenia: Treatment targets beyond monoamine systems'. Together they form a unique fingerprint.

Cite this